Ursodeoxycholic Acid Market Shows Boosted Growth Rate 2018-2026 Estimated by Global Top Players
Ursodeoxycholic
acid (UDCA) is a bile acid
taken as either a tablet or liquid to treat gallstones and to treat
and prevent the progression of cystic fibrosis-related liver
disorder. UDCA modifies the bile acid pool by decreasing levels of
hydrophobic bile acids while increasing proportion of nontoxic
hydrophilic bile acids. UDCA can delay development of
gastroesophageal varices and progression to cirrhosis. Moreover it
can improve long-term survival in patients with primary biliary
cirrhosis.
Significant
improvement in liver health can be achieved during UDCA therapy in
patients with intrahepatic cholestasis of pregnancy, primary
sclerosing cholangitis, nonalcoholic fatty liver disease, cystic
fibrosis-associated liver disease, total parenteral nutrition-induced
cholestasis, graft related liver disease, and in some pediatric
cholestatic liver diseases.
The global
ursodeoxycholic acid market size was valued at US$ 346.2 million in
2017, and is expected to witness a CAGR of 7.0% over the forecast
period (2018 – 2026).
Increasing prevalence of gall stones and cystic
fibrosis is expected to drive growth of the ursodeoxycholic acid
market
Ursodeoxycholic acid
is increasingly being used for the treatment of chronic cholestatic
liver diseases. Increasing prevalence of cystic fibrosis and gall
stones is a major factor driving growth of the global ursodeoxycholic
acid market during the forecast period. According to the Cystic
Fibrosis Foundation 2015 data, around 30,000 people suffered from
cystic fibrosis in the U.S. Moreover, around 1,000 new cases of
cystic fibrosis are diagnosed in the country, annually. According to
the American Gastroenterological Association 2017 report, gallstones
is affecting 10-15% of the U.S. population annually, which accounts
for around 25 million people.
Women are more likely
to develop gallstones in comparison to men. High estrogen levels
during pregnancy, birth control pills or hormone replacement therapy
are the major factors that produce gallstones in women. Moreover,
occurrence of gallstones is also high in older adults and individuals
with a family history of gallstones. Surgery is the usual treatment
for symptomatic gallstones, however treatment with ursodeoxycholic
acid can dissolve smaller stones, which are made mainly of
cholesterol.
Detailed Segmentation:
• Global
Ursodeoxycholic Acid Market, By Dosage Form:
◦ Liquid
◦ Solid
• Global
Ursodeoxycholic Acid Market, By Mode of Extraction:
◦ Synthetic
◦ Biological
• Global
Ursodeoxycholic Acid Market, By Application:
◦ Gallstones
◦ Cystic
Fibrosis
◦ Liver
Cirrhosis
◦ Others
• Global
Ursodeoxycholic Acid Market, By Region:
◦ North
America
▪ Europe
▪ Asia
Pacific
▪ Latin
America
▪ Middle
East
▪ Africa
Ursodeoxycholic Acid Market - Competitive
Landscape
Key players operating
in the global ursodeoxycholic acid market include, Abil Chempharma,
Arcelor Chemicals, Biotavia Labs, Daewoong Chemical, Dipharma
Francis, Erregierre, Grindeks, ICE, Mitsubishi Tanabe, Pharma Zell,
Suzhou Tianlu, and Zhangshanbelling.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2199
About Coherent Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702


Comments
Post a Comment